A Randomized, Controlled, Open-label, Multicenter Phase III Study of SHR-A1811 Combined With Adebrelimab for the First-line Treatment of Patients With HER2-overexpressing Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.

Start Date01 Dec 2026

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT07892625

/ Not yet recruitingPhase 1

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With Extensive Stage Small Cell Lung Cancer

This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.

Start Date15 Nov 2026

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

ChiCTR2600134798

/ Not yet recruitingPhase 2IIT

Efficacy and Safety of Trastuzumab Rezetecan Plus Adebrelimab and Capecitabine for Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Multicenter Tria

Start Date02 Nov 2026

Sponsor / Collaborator

The Affiliated Hospital of Qingdao University

100 Clinical Results associated with Adebrelimab

100 Translational Medicine associated with Adebrelimab

100 Patents (Medical) associated with Adebrelimab

Literatures (Medical) associated with Adebrelimab

31 Dec 2026·Future Science OA

Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?

Article

Author: Wu, Li-Peng ; Liu, Li ; Liu, Tao ; Min, Jie ; Sun, Si-Qin ; Xi, Heng

AIM:

To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.

OBSERVATION:

A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.

CONCLUSION:

This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.

01 Oct 2026·CANCER CELL

Hitting KRAS G12D without the gut punch: Can immunotherapy make it last?

Article

Author: Kim, Dae Won ; Garrido-Laguna, Ignacio

In this issue of Cancer Cell, Shi et al. report encouraging early-phase results combining HRS-4642, an allele-specific KRAS G12D inhibitor, with the PD-L1 inhibitor adebrelimab in previously treated metastatic pancreatic cancer. The intravenous combination was safe and well tolerated, notably sparing patients the gastrointestinal toxicity common to oral KRAS inhibitors, and achieved a promising 43% response rate at the recommended dose.

01 Oct 2026·CANCER CELL

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer

Article

Author: Xu, Jin ; Shi, Si ; Li, Jialin ; Hu, Xin ; Wang, Wei ; Du, Nan ; Yu, Xianjun ; Wei, Miaoyan ; Han, Boyue ; Luo, Fei

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.

News (Medical) associated with Adebrelimab

25 Oct 2026

·www.biospace.com

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma’s Emerging Innovation Power

BERLIN , Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 studies across 14 innovative therapeutic programs, including nine oral presentations, two mini oral sessions, and four late-breaking abstracts (LBAs), underscoring its global R&D strength. These data highlight the company's commitment to multi-cancer coverage and multi-mechanism innovation in oncology. In parallel, Hengrui scheduled a series of academic events, fostering in-depth dialogue with leading global experts and clinical researchers on cutting-edge topics in oncology. These initiatives established a dynamic platform for international academic exchange and infused Chinese innovation into the global landscape of cancer diagnosis and treatment – marking a new chapter in Hengrui's journey of international scientific engagement. As one of the world's premier oncology platforms, the ESMO Annual Congress attracts more than ten thousand experts and hundreds of leading international pharmaceutical companies each year. The meeting showcases the latest advances in cancer research and therapeutics, serving as a high-level hub for academic exchange and collaboration. It continues to catalyze innovation and clinical translation across the oncology community, aligning with the 2025 Congress vision: "Standing by those who care about cancer." Global Vision: China Innovation Going Global At the ESMO 2025 Annual Congress, Hengrui co-hosted the roundtable "China Innovation Going Global," bringing together leading Chinese and international experts to discuss strategic pathways and future prospects for the globalization of China-origin innovations. During the global launch of the CARES-009 study, featuring Hengrui's innovative therapeutic combination of camrelizumab and rivoceranib, Academician Jia Fan of the Chinese Academy of Sciences and Professor Jian Zhou of Zhongshan Hospital, Fudan University, jointly presented the latest global data from the study, garnering widespread attention from the international oncology community. Ms. Jo Feng, President and Chief Operating Officer of Hengrui Pharma, led the company's delegation at this year's Congress. She stated, "ESMO serves as a premier global platform for oncology exchange, and this year, Hengrui proudly presented 46 research achievements – highlighting our growing academic presence on the world stage. As an innovation-driven global pharmaceutical company, Hengrui places medical innovation at the heart of its strategic vision, with a steadfast commitment to addressing unmet clinical needs. Looking ahead, we remain firmly patient-centric, continuing to advance groundbreaking therapies to improve the lives of patients worldwide." Breakthroughs Across Multiple Cancer Types At this year's ESMO Annual Congress, Hengrui had 46 oncology research projects accepted, including four LBAs, spanning 14 innovative therapeutic programs. Among these, nine were selected for oral presentations, two for mini oral sessions, 32 as posters, and three as e-posters. Collectively, these studies encompass more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, pancreatic cancer, lung cancer, sarcoma, biliary tract cancer, head and neck squamous cell carcinoma, prostate cancer, and thyroid cancer. In breast cancer, Hengrui had 11 research studies accepted, comprising one oral presentation, one mini oral, eight posters, and one e-poster. Notably, an LBA featuring Hengrui's antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) compared with pyrotinib plus capecitabine for patients with HER2-positive advanced or metastatic breast cancer was selected for presentation. Multiple studies highlighting both established and emerging therapies, including pyrotinib, dalpiciclib, and adebrelimab, demonstrate Hengrui's deep and sustained commitment to advancing breast cancer research. In gastrointestinal cancers, 14 studies were accepted, including two oral presentations, 11 posters, and one e-poster. Alongside flagship therapies such as camrelizumab and rivoceranib, four studies on adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in advancing care for patients with gastrointestinal malignancies. In lung cancer, six poster presentations featuring camrelizumab and adebrelimab were accepted, underscoring Hengrui's expanding footprint in this therapeutic area. These studies covered both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), further validating the clinical potential and versatility of these regimens. Across additional disease areas, including gynecologic tumors, thymic epithelial tumors, head and neck squamous cell carcinoma, sarcoma, prostate cancer, and thyroid cancer, Hengrui had 13 studies accepted, featuring a diverse range of innovative therapies such as camrelizumab, fuzuloparib, rivoceranib, rezvilutamide, adebrelimab, famitinib, HRS-7058, and HRS-4642. These included six oral presentations, one mini oral, five posters, and one e-poster, highlighting Hengrui's robust and broad-based R&D capabilities. In addition, two posters were accepted on hetrombopag and ondansetron oral soluble films, focusing on the prevention and management of chemotherapy-induced thrombocytopenia, nausea, and vomiting. Dr. Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, stated: "At this year's ESMO Annual Congress, we unveiled a broader and more impactful portfolio of research findings. The concentrated release of these breakthrough data not only reflects Hengrui's robust R&D capabilities, but also highlights the results of our science-driven, globally oriented innovation R&D strategy. Our pipeline is both deep and forward-looking – while reinforcing our existing product portfolio, we are also actively expanding into cutting-edge therapeutic areas. We firmly believe that through this in-depth engagement with the global oncology community, we can better enable our breakthroughs to benefit more patients worldwide." A Decade of ESMO Participation: China Innovation Going Global Since 2016, Hengrui Oncology has participated in the ESMO Annual Congress for 10 consecutive years, consistently setting new benchmarks for Chinese pharmaceutical companies. Between 2023 and 2025, Hengrui presented a total of 119 research achievements: 2023: 36 studies accepted, including two preferred oral presentations, six mini oral presentations, and 28 posters, covering multiple therapeutic areas such as gastrointestinal cancers, breast cancer, cervical cancer, pancreatic cancer, and melanoma. 2024: 37 studies accepted, spanning 13 innovative therapies and more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, and lung cancer. 2025: Marking its first-ever exhibition booth at ESMO, Hengrui presented 46 studies across 14 innovative medicines. This milestone represents a significant step forward in Hengrui's internationalization strategy and its commitment to advancing global cancer care. Commitment to Global Impact with the Promise of Patient Focus Hengrui remains steadfast in its commitment to science and innovation driven by the goal of addressing unmet patient needs. Leveraging a global R&D network, the company is advancing innovative medicines onto the international stage. Through a strategically structured pipeline, continuous breakthroughs across multiple cancer types, and active participation in global academic exchange, Hengrui Oncology is accelerating the internationalization and bringing new hope and broader treatment options to patients worldwide. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Hengrui Oncology Hengrui Oncology specializes in the development, production, and global commercialization of innovative cancer therapies. It is the first business unit within Hengrui to achieve technological breakthroughs and successfully enter international markets. Hengrui Oncology has established a robust and diversified oncology pipeline encompassing multiple tumor types, with a comprehensive portfolio that includes immunotherapies, targeted therapies, and ADCs. In key areas such as breast cancer, Hengrui Oncology provides full-course treatment solutions that span multiple lines of therapy. To date, 14 novel oncology agents developed by Hengrui have been approved for marketing in China. View original content: SOURCE Hengrui Pharma

ASCOImmunotherapyDrug Approval

21 Oct 2026

·www.prnewswire.com

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care. More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted antibody-drug conjugates (ADCs) in breast and lung cancers, advancing research on novel targets and exploring their clinical value across a range of applications. Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while developing new approaches for difficult-to-treat cancers such as pancreatic cancer. Hengrui puts patient needs at the center of its mission to deliver life-changing clinical value. SHANGHAI, Oct. 20, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 will take place in Madrid, Spain, from October 23 to 27. Hengrui Pharma will present 64 research findings at the congress, including three studies accepted for Proffered Paper presentations, three for Rapid Oral presentations, 32 for Posters and 26 for e-Posters. The ESMO Congress is a major global platform for innovative oncology drug development and scientific exchange. Hengrui Pharma has participated for 11 consecutive years since 2016, with a total of 119 research findings accepted between 2023 and 2025. This year, the number of accepted findings continues to grow, covering more than ten cancer areas, including esophageal, gastric, liver, biliary tract, pancreatic, rectal, breast, lung, cervical, prostate and nasopharyngeal cancers, as well as thymic epithelial tumors and sarcomas. The company will also host an exhibition booth for the second consecutive year, showcasing its latest progress in exploring novel targets, expanding the clinical value of its products, and developing its innovative pipeline. Proffered Paper Presentations Highlight Novel Targets as Hengrui Pharma Advances ADC Innovation Two independently developed ADCs from Hengrui Pharma, the HER2-targeted trastuzumab rezetecan (SHR-A1811) and the HER3-targeted ruzaltatug rezetecan (SHR-A2009), have both been selected for Proffered Paper presentations at the ESMO Congress. The studies address clinical treatment needs in breast and lung cancers, respectively. The data from these studies will be presented during the congress. The Proffered Paper presentation on trastuzumab rezetecan will focus on progress from HORIZON-Breast06, a randomized phase 3 study in HER2-low advanced breast cancer, led by principal investigator Academician Binghe Xu of the Cancer Hospital at the Chinese Academy of Medical Sciences. One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, gastric, colorectal and cervical cancers. It is also among the innovative medicines with the highest number of breakthrough therapy designations in China. The study will further explore the therapeutic potential of trastuzumab rezetecan in this patient population and provide new evidence to support the expansion of its clinical applications. The congress will also feature interim analyses from HERON-Lung01, a phase 3 trial comparing ruzaltatug rezetecan (SHR-A2009) with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small-cell lung cancer that has progressed after EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The trial is led by principal investigator Professor Yi-Long Wu of Guangdong Provincial People's Hospital. In July 2026, following positive results from HERON-Lung01, China's National Medical Products Administration (NMPA) accepted for review the marketing application for ruzaltatug rezetecan, intended to treat adults with EGFR-mutated locally advanced or metastatic non-squamous NSCLC whose disease has progressed following EGFR-TKI therapy. In addition, a Phase III clinical trial is currently underway to evaluate ruzaltatug rezetecan in combination with EGFR TKI as a first-line treatment for patients with EGFR-mutated locally advanced or metastatic NSCLC. Outside China, ruzaltatug rezetecan has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of patients with EGFR-mutated metastatic NSCLC whose disease has progressed following treatment with a third-generation EGFR-TKI and platinum-based chemotherapy.[1] As development progresses from early exploration to larger-scale evaluation of efficacy, the latest findings on ruzaltatug rezetecan will provide new clinical evidence on the therapeutic potential of HER3-targeted ADCs in patients with non-small-cell lung cancer. With HER2 and HER3 among its key targets, Hengrui Pharma has built an ADC development pipeline spanning multiple targets and continues to expand potential applications across cancer types and treatment settings. Its portfolio combines further development of established targets with exploration of emerging targets. Advancing Commercialization and R&D Innovation to Expand Clinical Value At this year's ESMO Congress, Hengrui Pharma will also present the latest research findings from its established products and innovative pipeline. Camrelizumab, a domestically developed PD-1 inhibitor with a leading number of approved indications and cancer types covered, will be featured in a Proffered Paper presentation about UNION, a phase 3 trial of neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer. Hengrui Pharma will also use the Rapid Oral session to present the latest findings on its phase 2 study into Nectin-4-targeted ADC SHR-A2102 in recurrent or metastatic cervical cancer, providing evidence to support further exploration of its clinical development potential in additional cancer types. Alongside expanding existing treatment options, Hengrui Pharma is actively pursuing therapies for difficult-to-treat cancers such as pancreatic cancer. A combination regimen based on its independently developed KRAS G12D inhibitor HRS-4642 has been selected for a Rapid Oral presentation. This presentation will feature preliminary results from a phase 2 study of HRS-4642 plus chemotherapy, with or without adebrelimab, as perioperative therapy for KRAS G12D-mutant pancreatic cancer. HRS-4642 injection in combination with gemcitabine and nab-paclitaxel has been granted breakthrough therapy designation by the CDE of the NMPA for the first-line treatment of advanced or metastatic pancreatic cancer with a KRAS G12D mutation[2]. The research may offer new treatment possibilities for patients with pancreatic cancer and new approaches to exploring targeted therapies for KRAS mutations. From expanding the clinical value of established products to pursuing advances in its innovative pipeline and difficult-to-treat cancers, Hengrui Pharma continues to drive clinical value through R&D innovation, opening up more treatment possibilities for patients with cancer. Expanding Development Pathways to Bring Chinese Innovation to the World Following its first exhibition booth in 2025, Hengrui Pharma will again host a booth at this year's ESMO Congress, providing a platform for international scientific exchange on its innovative products and related research. Representatives from Hengrui Pharma's leading R&D and innovation teams will also attend the congress to engage with oncology experts and researchers from around the world and explore how pharmaceutical innovation can benefit more patients globally. Jo Feng, President and COO of Hengrui Pharma, said: "This year marks the eleventh time we have participated in ESMO, with 64 research presentations - a new record for Hengrui. We look forward to sharing our latest advances in innovative drug development, presenting clinical evidence demonstrating meaningful benefits for patients, and bringing more Chinese innovation to benefit patients worldwide." Hengrui Pharma will present additional research data and updates throughout this year's ESMO Congress, further demonstrating the exploration and development of innovative Chinese medicines in global oncology. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn. About Hengrui Oncology Hengrui Oncology is one of Hengrui Pharma's core strategic business areas. Following decades of development, it has established a comprehensive portfolio spanning seven major disease areas, including gastrointestinal and breast cancers, as well as oncology supportive care. As of June 2026, 14 independently developed Class 1 innovative medicines, including AiRuiKa® (Camrelizumab for Injection), HengQu® (Herombopag Olamine Tablets) and AiWeiDa® (Trastuzumab Rezetecan for Injection), had been launched in China. Supported by its global R&D system and a range of international collaborations, Hengrui Oncology is accelerating its transition from innovation in China to innovation for the world, offering more precise, accessible and high-quality treatment options for patients with cancer. For more information, please visit: Appendix: Presentation Schedule for Key Hengrui Oncology Studies at ESMO Congress 2026 ( link ) As of 19 October, 2026 Abstract number: LBA13 Study title: Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): a randomized, phase 3 study (HORIZON-Breast06) Presenter: Ying Fan (Cancer Hospital, Chinese Academy of Medical Sciences) Session name: Proffered paper 1: Breast cancer, early and advanced stage Session time: October 23, 13:40 - 13:50 (local time) Therapeutic area / subcategory: Breast cancer Product: Trastuzumab rezetecan (SHR-A1811) Venue: Alicante Auditorium, Hall 6 Abstract number: LBA72 Study title: Ruzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trial Presenter: Chongrui Xu (Guangdong Provincial People's Hospital) Session name: Proffered paper 2: NSCLC, metastatic Session time: October 26, 09:24 - 09:34 (local time) Therapeutic area / subcategory: Lung cancer / Non-small-cell lung cancer Product: Ruzaltatug rezetecan (SHR-A2009) Venue: Alicante Auditorium, Hall 6 Abstract number: LBA85 Study title: HRS-4642 Plus Chemotherapy ± Adebrelimab as Perioperative Therapy in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results of a Phase 2 Study Presenter: Chenlei Wen (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine) Session name: Rapid oral 2: Gastrointestinal tumour, upper digestive Session time: October 26, 14:45 - 14:50 (local time) Therapeutic area / subcategory: Gastrointestinal cancers / Pancreatic cancer Products: HRS-4642 ± adebrelimab Venue: Barcelona Auditorium, Hall 9 Abstract number: 3530O Study title: Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial Presenter: Zhen Yu Lin (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) Session name: Proffered paper: Gastrointestinal tumours, lower digestive Session time: October 25, 11:10 - 11:20 (local time) Therapeutic area / subcategory: Gastrointestinal cancers / Rectal cancer Product: Camrelizumab Venue: Almeria Auditorium - Hall 9 Abstract number: 1244RO Study title: SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study Presenter: Jieping Chen (Sun Yat-sen University Cancer Center) Session name: Rapid oral 1: Gynaecological cancers Session time: October 23, 16:20 - 16:25 (local time) Therapeutic area / subcategory: Gynecological cancers / Cervical cancer Product: SHR-A2102 Venue: Burgos Auditorium - Hall 3 Abstract number: 4155RO Study title: Rivoceranib in patients with pretreated metastatic thymic epithelial tumors: phase II multi-center KCSG LU23-09 (THRIVE) trial Presenter: Sehhoon Park (Seoul, Republic of Korea) Session name: Rapid oral: Non-metastatic NSCLC and other thoracic malignancies Session time: October 26, 11:02 - 11:07 (local time) Therapeutic area / subcategory: Other / Thymic epithelial tumors Product: Apatinib Venue: Burgos Auditorium - Hall 3 SOURCE Hengrui Pharma 21% more press release views with Request a Demo

Phase 2Phase 3Fast TrackBreakthrough TherapyClinical Result

20 Oct 2026

·www.prnewswire.com

Hengrui Pharma Previews ESMO Congress 2026 with 64 Research Findings Across Its Innovative Oncology Portfolio

64 findings accepted, including three Proffered Paper and three Rapid Oral presentations, spanning more than ten oncology and supportive care areas. More than ten studies highlight HER2- and HER3-targeted antibody-drug conjugates (ADCs) in breast and lung cancers. Research advances established products and innovative therapies, including approaches for difficult-to-treat cancers such as pancreatic cancer. SHANGHAI, Oct. 20, 2026 /PRNewswire/ -- Hengrui Pharma will present 64 research findings at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from October 23 to 27, 2026. These include three Proffered Paper presentations, three Rapid Oral presentations, 32 Posters and 26 e-Posters. Participating for the eleventh consecutive year, Hengrui Pharma will share progress across more than ten cancer areas and host an exhibition booth for the second consecutive year. Advancing ADC Innovation in Breast and Lung Cancers Two independently developed ADCs, HER2-targeted trastuzumab rezetecan (SHR-A1811) and HER3-targeted ruzaltatug rezetecan (SHR-A2009), have been selected for Proffered Paper presentations. These studies address treatment needs in breast and lung cancers. Trastuzumab rezetecan will feature in HORIZON-Breast06, a randomized phase 3 study in HER2-low advanced breast cancer led by Academician Binghe Xu of the Cancer Hospital at the Chinese Academy of Medical Sciences. The findings will further explore its therapeutic potential in this patient population. Trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, gastric, colorectal and cervical cancers. HERON-Lung01, led by Professor Yi-Long Wu of Guangdong Provincial People's Hospital, will present interim analyses comparing ruzaltatug rezetecan with platinum-based chemotherapy in EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. China's National Medical Products Administration accepted its marketing application for review in July 2026. The ADC has also received US Food and Drug Administration Fast Track designation for EGFR-mutated metastatic NSCLC progressing after a third-generation EGFR-TKI and platinum-based chemotherapy. A phase 3 trial is also evaluating ruzaltatug rezetecan with an EGFR-TKI as first-line treatment for EGFR-mutated locally advanced or metastatic NSCLC. With HER2 and HER3 among its key targets, Hengrui Pharma has built an ADC development pipeline spanning multiple targets and continues to expand potential applications across cancer types and treatment settings. Its portfolio combines further development of established targets with exploration of emerging targets. Expanding Clinical Value Across Established and Emerging Therapies Hengrui Pharma's established PD-1 inhibitor camrelizumab will feature in UNION, a phase 3 trial of neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer. A Rapid Oral presentation will share phase 2 findings on Nectin-4-targeted ADC SHR-A2102 in recurrent or metastatic cervical cancer. Another Rapid Oral presentation will report preliminary phase 2 results for KRAS G12D inhibitor HRS-4642 plus chemotherapy, with or without adebrelimab, as perioperative therapy for KRAS G12D-mutant pancreatic cancer. HRS-4642 combined with gemcitabine and nab-paclitaxel has received breakthrough therapy designation in China for first-line treatment of advanced or metastatic KRAS G12D-mutant pancreatic cancer. Sharing Chinese Innovation with the Global Oncology Community Hengrui Pharma's R&D and innovation teams will join oncology experts and researchers at the congress, supporting international scientific exchange on its innovative products and research. Jo Feng, President and COO of Hengrui Pharma, said: "This year marks the eleventh time we have participated in ESMO, with 64 research presentations - a new record for Hengrui. We look forward to sharing our latest advances in innovative drug development, presenting clinical evidence demonstrating meaningful benefits for patients, and bringing more Chinese innovation to benefit patients worldwide. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn. 21% more press release views with Request a Demo

Phase 2Phase 3Fast TrackBreakthrough TherapyADC

100 Deals associated with Adebrelimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	23 Jun 2026
Extensive stage Small Cell Lung Cancer	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	28 Feb 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-positive Non-squamous non-small cell lung cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	01 Dec 2026
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	01 Dec 2026
Gastroesophageal junction adenocarcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	07 May 2026
Gastroesophageal junction adenocarcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	07 May 2026
Gastrooesophageal junction cancer	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	07 May 2026
Gastrooesophageal junction cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	07 May 2026
Locally Advanced Rectal Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	23 Mar 2026
Advanced biliary tract cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	21 Jan 2026
Advanced Cervical Carcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	08 Oct 2025
Locally Advanced Cervical Carcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	08 Oct 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06405061 (ESMO2026)	Phase 2	Hepatocellular Carcinoma First line	23	Adebrelimaberial infusion chemotherapy (HAIC) + Adebrelimab + Adebrelimab	ospdmybkkw(atekfhuskl) = pmatqylocw tvixjqnrbe (ynjaaxwfvv ) View more	Positive	23 Oct 2026
NCT06663059 (ESMO2026)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	80	Adebrelimab + albumin-bound paclitaxel and cisplatin for 2 cycles	xbufgyzbuk(dgwvlysbpr) = sheetiiolf gfmbffxmym (yhhcqftgvn ) View more	Positive	23 Oct 2026
NCT06663059 (ESMO2026)	Phase 2		80	Adebrelimab + albumin-bound paclitaxel and cisplatin for 4 cycles	xbufgyzbuk(dgwvlysbpr) = dgfvwsxdli gfmbffxmym (yhhcqftgvn ) View more	Positive	23 Oct 2026
NCT05738317 (ESMO2026)	Phase 2	Squamous non-small cell lung cancer Second line driver mutation-negative	46	Adebrelimab plus bevacizumab and nab-paclitaxel	rpbhbvfugc(huefdscatc) = igslzbcjly mrhfvwwgaa (eujduzaemq, 45.9 - 74.9) View more	Positive	23 Oct 2026
ChiCTR2300079125 (ESMO2026)	Phase 2	Extensive stage Small Cell Lung Cancer First line	65	Adebrelimab plus platinum-etoposide	izcrcitzdn(qtvpqkjdrg) = qwlgtydltk wiumokrkcw (qwyxdyidnz, 45.8 - 71.8) View more	Positive	23 Oct 2026
NCT07131514 (ESMO2026)	Phase 2	KRAS Mutant Pancreatic Cancer Adjuvant \| Neoadjuvant KRAS G12D	30	HRS-4642 + GnP + adebrelimab	fuzsyojxuz(cidzjhcrxf) = yknedfswyh atgvsvyaal (gkwrlxffps ) View more	Positive	23 Oct 2026
NCT06465563 (ESMO2026)	Phase 2	Advanced biliary tract cancer First line	80	SHR-8068 plus adebrelimab and gemcitabine/cisplatin (GC)	mvnordoizp(ahuqermolo) = hrqsgzpjwv lvzxaiwaeh (iokzmsppnw, 29.3 - 61.5) View more	Positive	23 Oct 2026
NCT06465563 (ESMO2026)	Phase 2	Advanced biliary tract cancer First line	80	adebrelimab plus GC	mvnordoizp(ahuqermolo) = xpacxbtvah lvzxaiwaeh (iokzmsppnw, 14.6 - 43.9) View more	Positive	23 Oct 2026
ChiCTR2500100571 (ESMO2026)	Phase 2	Non-Small Cell Lung Cancer Neoadjuvant	40	Adebrelimab+anlotinib+chemotherapy	mrzgialyib(dvewcfqtlu) = riyurxafoc satpuxcndu (plqjqtjbwo ) View more	Positive	23 Oct 2026
NCT06784206 (ASTRO2026)	Phase 2	Small cell lung cancer limited stage Maintenance	17	Adebrelimab 1200 mg	xyyzhxjpgn(jhdtdhfray) = Treatment-related adverse events (TRAEs) occurred in 41.2% of patients (all Grade 1-2), including pneumonia (29.4%), anorexia (23.5%), and radiation pneumonitis (11.8%). No Grade 3 or higher TRAEs were observed. okkuqsiytv (tydpvbswlw ) View more	Positive	27 Sep 2026
WCLC2026	Phase 2	Small cell lung cancer limited stage Neoadjuvant	40	Adebrelimab + Chemotherapy (3 cycles)	anaixxvuma(wfxhyxkpuv) = clrzleebni yrjivbdbny (ougeeexfhl ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Small Cell Lung Cancer Neoadjuvant	51	chemotherapy + Adebrelimab	jkonduoagl(fmapihpijh) = ewjxnsqccg ajmamjksqh (yqexsptgco ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Small Cell Lung Cancer Neoadjuvant	51	chemotherapy	jkonduoagl(fmapihpijh) = hpihehqgze ajmamjksqh (yqexsptgco ) View more	Positive	12 Sep 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis